#USA #Veeva Systems #Life Sciences #Pleasanton #Ostro

Veeva Systems Acquires Ostro: A Game-Changer in Life Sciences Engagement

In a significant move poised to reshape the landscape of brand engagement in the life sciences sector, Veeva Systems (NYSE: VEEV) announced the acquisition of Ostro, the foremost platform specializing in brand engagement for life sciences. This strategic acquisition, estimated at around $100 million in cash and stock, was made public on March 10, 2026, and aims to enhance how healthcare professionals and patients interact with vital information.

Understanding the Role of Ostro

Ostro is recognized for its innovative approach, utilizing a user-friendly interface backed by cutting-edge AI technology to deliver compliant and timely responses to patients and doctors alike. With its platform, users can easily navigate to important information, approved resources, and actionable next steps through intuitive chat functionalities. This elevates the patient experience by ensuring they get accurate answers precisely when they need them.

This engagement platform stands out by employing a powerful combination of conversational AI, semantic search, and industry-specific regulations to ensure that all responses are compliant with medical, legal, and regulatory standards. Unlike typical AI solutions that can sometimes produce unverified outputs, Ostro guarantees that the information it provides is 100% accurate and validated through rigorous processes, thereby eliminating potential misinformation that could arise in such sensitive sectors.

Insights from the Leadership

Peter Gassner, Veeva's CEO, emphasized the changing landscape of information gathering in his statement: "The use of AI has transformed the manner in which information is disseminated. Nowadays, the emphasis lies more on how easily clients can access the answers they need, rather than the sheer volume of data available. Ostro leads the way by facilitating instant access to accurate information for both patients and healthcare professionals. We are excited to welcome Ostro into the Veeva family as we pioneer the future of AI-powered client engagement."

Chase Feiger, the CEO of Ostro, also shared his vision, stating, "Our primary goal is to minimize the time needed for diagnosing and addressing health issues. The information provided by brands should be readily accessible and designed to meet compliance standards from the outset. We’ve built Ostro to dissolve barriers, enabling patients and physicians to obtain reliable answers with fewer clicks and less searching. Partnering with Veeva allows us to extend this seamless experience to a broader audience, including more patients, doctors, and brands."

The Future of Ostro Within Veeva

Despite being acquired, Ostro is set to operate as an independent unit under the guidance of Chase Feiger. This independence is pivotal as the company plans to integrate its services with Veeva's Commercial Cloud applications. These integrations are anticipated to foster smooth workflows that connect online engagements with real-world interactions, greatly enhancing the customer-centric approach Veeva has been known for.

For those interested in exploring Ostro's services or understanding more about their capabilities, further information can be found at ostro.veeva.com.

About Veeva Systems

Veeva Systems provides a specialized cloud platform for the life sciences industry, offering software, data, and consulting services to firms in the sector. With a commitment to innovation, product excellence, and customer success, Veeva serves over 1,500 clients, including the largest global biopharmaceutical companies and emerging biotech firms. As a public company, Veeva is dedicated to balancing the interests of all stakeholders - customers, employees, shareholders, and the sectors it serves. To learn more, visit veeva.com.

Looking Ahead

As Veeva embarks on this latest venture, the industry remains eager to observe how the enhanced capabilities of Ostro will transform client engagement in the life sciences sector. With the focus on compliance and patient-centered solutions, the stakes have never been higher for both companies in this evolving landscape.